Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 4/19/17 → 1/23/19 |
Funding
- Novartis (domestic): $25,174.00
16-GI-100-NP (PDR001) An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Advanced or Metastatic Non-Functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin, Who Have Progressed
- Anthony, Lowell (PI)
- Arnold, Susanne (CoI)